Annotation Detail

Information
Associated Genes
ABL1
Associated Variants
ABL1 p.Phe378Val (p.F378V) ( ENST00000318560.6, ENST00000372348.9 )
ABL1 p.Phe378Val (p.F378V) ( ENST00000318560.6, ENST00000372348.9 )
Associated Disease
chronic myeloid leukemia
Source Database
CIViC Evidence
Description
In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. Resulting clones were grown in a range of tyrosine kinase inhibitor concentrations to identify resistance mutations. The F359V mutation was associated with resistance in 2 μM imatinib (3 clones recovered, ~2%). In a review of 20 publications, this mutation was previously described in imatinib resistant patients.
Variant Origin
somatic
Variant Origin
Somatic
Evidence URL
https://civic.genome.wustl.edu/links/evidence_items/6256
Gene URL
https://civic.genome.wustl.edu/links/genes/4
Variant URL
https://civic.genome.wustl.edu/links/variants/892
Rating
2
Evidence Type
Predictive
Disease
Chronic Myeloid Leukemia
Evidence Direction
Supports
Drug
Imatinib Mesylate
Evidence Level
D
Clinical Significance
Resistance
Pubmed
16772610
Drugs
Drug NameSensitivitySupported
Imatinib MesylateResitance or Non-Reponsetrue